International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
- PMID: 23770307
- DOI: 10.1016/j.vaccine.2013.06.032
International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
Abstract
Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination.
Methods: The primary analysis used the self-controlled case series (SCCS) design to estimate the relative incidence (RI) of GBS in the 42 days following vaccination with pH1N1 vaccine in a pooled analysis across databases and in analysis using a meta-analytic approach.
Results: We found a relative incidence of GBS of 2.42 (95% CI 1.58-3.72) in the 42 days following exposure to pH1N1 vaccine in analysis of pooled data and 2.09 (95% CI 1.28-3.42) using the meta-analytic approach.
Conclusions: This study demonstrates that international collaboration to evaluate serious outcomes using a common protocol is feasible. The significance and consistency of our findings support a conclusion of an association between 2009 H1N1 vaccination and GBS. Given the rarity of the event the relative incidence found does not provide evidence in contradiction to international recommendations for the continued use of influenza vaccines.
Keywords: Adjuvant; Adverse events following immunization (AEFI); CPRD; CSF; Clinical Practice Research Datalink; Department of Defense; Department of Veterans Affairs; DoD; GP; Guillain Barré Syndrome (GBS); ICPI; Integrated Primary Care Information Database; International; MCRI; Maccabi; Maccabi Health Maintenance Organization; Monovalent H1N1 Vaccine (H1N1); Murdoch Children's Research Institute; NNI/CGH; NNI/TTSH; National Neuroscience Institute Singapore General Hospital; National Neuroscience Institute Tan Tock Seng Hospital; PRISM; Post-Licensure Rapid Immunization Safety Monitoring; Self-controlled case-series method (SCCS); VA; VAESCO; VSD; Vaccine Adverse Event Surveillance and Communication Consortium; Vaccine Safety Datalink; cerebrospinal fluid; general practitioner.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.Clin Infect Dis. 2014 Apr;58(8):1149-55. doi: 10.1093/cid/ciu005. Epub 2014 Jan 9. Clin Infect Dis. 2014. PMID: 24415636 Review.
-
Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe.PLoS One. 2014 Jan 3;9(1):e82222. doi: 10.1371/journal.pone.0082222. eCollection 2014. PLoS One. 2014. PMID: 24404128 Free PMC article.
-
Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010.Am J Epidemiol. 2013 Sep 15;178(6):962-73. doi: 10.1093/aje/kwt051. Epub 2013 May 6. Am J Epidemiol. 2013. PMID: 23652165
-
Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.Lancet. 2013 Apr 27;381(9876):1461-8. doi: 10.1016/S0140-6736(12)62189-8. Epub 2013 Mar 13. Lancet. 2013. PMID: 23498095
-
Guillain-Barré syndrome after exposure to influenza virus.Lancet Infect Dis. 2010 Sep;10(9):643-51. doi: 10.1016/S1473-3099(10)70140-7. Lancet Infect Dis. 2010. PMID: 20797646 Review.
Cited by
-
Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.Front Immunol. 2022 Dec 9;13:1038411. doi: 10.3389/fimmu.2022.1038411. eCollection 2022. Front Immunol. 2022. PMID: 36569912 Free PMC article. Review.
-
Information systems for vaccine safety surveillance.Hum Vaccin Immunother. 2022 Nov 30;18(6):2100173. doi: 10.1080/21645515.2022.2100173. Epub 2022 Sep 26. Hum Vaccin Immunother. 2022. PMID: 36162040 Free PMC article. Review.
-
Guillain-Barré syndrome following influenza vaccination: A 15-year nationwide population-based case-control study.Eur J Neurol. 2022 Nov;29(11):3389-3394. doi: 10.1111/ene.15516. Epub 2022 Aug 13. Eur J Neurol. 2022. PMID: 35913431 Free PMC article.
-
Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.JAMA Netw Open. 2022 Mar 1;5(3):e222940. doi: 10.1001/jamanetworkopen.2022.2940. JAMA Netw Open. 2022. PMID: 35297971 Free PMC article.
-
Interpretation of vaccine associated neurological adverse events: a methodological and historical review.J Neurol. 2022 Jan;269(1):493-503. doi: 10.1007/s00415-021-10747-8. Epub 2021 Aug 16. J Neurol. 2022. PMID: 34398270 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical